Loading organizations...

§ Private Profile · Lausanne, Switzerland
Automated cloud lab for protein engineering, offering synthesis and testing for biotech and pharma, focused on AI-designed proteins.
Adaptyv has raised $10.8M across 3 funding rounds.
Key people at Adaptyv.
Adaptyv was founded in 2020 by Julian Englert (Founder) and Daniel Nakhaee-Zadeh Gutierrez (Founder).
Adaptyv has raised $10.8M in total across 3 funding rounds.
Adaptyv Bio is an Épalinges, Switzerland-based biotechnology company that builds fully automated cloud laboratories for protein engineering, enabling the rapid synthesis, testing, and validation of AI-designed proteins. The platform integrates synthetic biology, robotics, microfluidics, and cell-free systems to automate the entire design-test-learn cycle for researchers developing therapeutics, industrial enzymes, and advanced materials. Operating with a team of 25 employees, the organization has successfully synthesized and screened more than 10,000 proteins for over 30 pharmaceutical and biotech research teams. To support its expansion, the enterprise has secured approximately $10.5 million in total venture capital funding, including a recent $8 million seed round, backed by prominent institutional investors such as Y Combinator, Ace Ventures, ByFounders, and Founderful. Adaptyv Bio was founded in 2021 by co-founders Julian Englert, Daniel Nakhaee-Zadeh Gutierrez, Amir Shahein, and Moustafa Houmani.
Key people at Adaptyv.
Adaptyv was founded in 2020 by Julian Englert (Founder) and Daniel Nakhaee-Zadeh Gutierrez (Founder).
Adaptyv has raised $10.8M in total across 3 funding rounds.
Adaptyv's investors include ACE Venture, byFounders, LongGame, Acequia Capital, Axial, FAST by GETTYLAB, Founders Inc., Hawktail, Rheingau Founders, S2S Ventures, Venture Kick, Y Combinator.
Adaptyv Bio is building a fully automated, cloud-based laboratory platform designed to accelerate protein engineering by seamlessly integrating AI-driven protein design with rapid experimental validation. Their platform combines advanced robotics, microfluidics, and synthetic biology to enable protein engineers to test thousands of AI-generated protein variants in parallel with drastically reduced reagent use and turnaround times as short as three weeks. This innovation addresses a critical bottleneck in protein engineering by providing high-quality experimental data that improves AI models and speeds up the design–test–learn cycle. Adaptyv serves biotech companies, pharmaceutical firms, AI research labs, and startups focused on therapeutic and industrial protein development, helping them validate protein designs faster, cheaper, and more reliably, thus fueling growth in AI-powered biotech innovation[1][2][3][4][6].
Founded by Julian Englert (CEO) and Daniel Nakhaee-Zadeh (CTO), Adaptyv Bio emerged from the recognition that while AI can generate vast numbers of protein designs computationally, experimental validation remains slow, costly, and complex. Englert, with a background in materials science and biomedical technologies, and experience in health-tech startups, co-founded Adaptyv to build an integrated, automated protein foundry that miniaturizes and automates lab processes. Since its beta launch, Adaptyv has tested over 10,000 proteins with more than 30 partners worldwide, demonstrating significant improvements in protein success rates and validating its approach[3][5][7].
Adaptyv rides the convergence of AI, automation, and synthetic biology—a key trend driving the biorevolution. As AI models for protein design improve, experimental validation has become the limiting factor in bringing new proteins to market. Adaptyv’s platform addresses this gap by making wet lab validation scalable, programmable, and integrated with computational design. This timing is critical as demand for novel proteins in medicine, industrial enzymes, and materials surges. By enabling faster iteration cycles and lowering costs, Adaptyv accelerates innovation across biotech and pharma, influencing the broader ecosystem by democratizing access to high-throughput protein engineering infrastructure[1][3][4][7].
Looking ahead, Adaptyv plans to scale its lab capacity, diversify biochemical assays, and release APIs to connect AI design tools directly to their automated lab workflows. This will further streamline the design–test–learn loop and expand the range of protein applications supported. Trends such as increasing AI adoption in biotech, demand for sustainable enzymes, and personalized medicine will shape their growth trajectory. As Adaptyv matures, it is poised to become a foundational infrastructure provider in the AI-powered protein engineering space, potentially enabling a million new protein designers worldwide and transforming how biology is engineered[3][6][7].
Adaptyv has raised $10.8M across 3 funding rounds. Most recently, it raised $8.0M Adaptyv Biosystems - Seed in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 25, 2025 | $8M Seed | ACE Venture | ByFounders, Longgame | Announced |
| Feb 14, 2022 | $2.5M Pre Seed | — | Acequia Capital, Axial, FAST BY GETTYLAB, Founders Inc., Hawktail, Rheingau Founders, S2S Ventures, Venture Kick, Y Combinator | Announced |
| Aug 4, 2021 | $270K Grant | Y Combinator | — | Announced |